Genetic Architecture of Autoimmune Diseases

Information

  • Research Project
  • 6784640
  • ApplicationId
    6784640
  • Core Project Number
    R43AI056639
  • Full Project Number
    5R43AI056639-02
  • Serial Number
    56639
  • FOA Number
    PA-01-52
  • Sub Project Id
  • Project Start Date
    8/1/2003 - 21 years ago
  • Project End Date
    7/31/2005 - 19 years ago
  • Program Officer Name
    SERRATE-SZTEIN, SUSANA
  • Budget Start Date
    8/1/2004 - 20 years ago
  • Budget End Date
    7/31/2005 - 19 years ago
  • Fiscal Year
    2004
  • Support Year
    2
  • Suffix
  • Award Notice Date
    8/27/2004 - 20 years ago
Organizations

Genetic Architecture of Autoimmune Diseases

[unreadable] DESCRIPTION (provided by applicant): Phenotypic and genetic markers are urgently needed in autoimmune diseases for early and accurate diagnosis and monitoring disease progression and therapeutic intervention. We are proposing comprehensive phenotypic analysis for the identification of biological markers and genetic mapping of these quantifiable inheritable traits. Rheumatoid Arthritis (RA), a chronic inflammatory disorder that preferentially affects women will serve as a model disease. This application describes SurroMed's comprehensive phenotyping platform and the power of genetic analysis conducted at Myriad Genetics using a rich resource of family material. Phase I focuses on recruitment of RA multi-case families, technology development, and an initial analysis of human serum from affected RA family members and unaffected first-degree relatives. The approach includes both broad discovery-based and hypothesis-driven strategies. We will test the hypothesis that there are multiple quantitative differences in cellular and serum phenotypic variables between RA subjects and unaffected first-degree relatives. If our efforts are successful, in Phase II, we will test the hypothesis that variation in the levels of multiple biomarkers are significantly inheritable. Potential results of the work include biomarker and genetic products for the clinical assessment of disease. The methods developed here will also be broadly applicable to other conditions, especially autoimmune and immunological diseases. [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    300000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:300000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SURROMED, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    MENLO PARK
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    940251432
  • Organization District
    UNITED STATES